BioTime appoints Stephana Patton as general counsel
BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.
Dr. Patton brings more than 17 years of experience, creating portfolio value at publicly-traded biotechnology and pharmaceutical companies. She was most recently general counsel and commercial compliance officer at BioDelivery Sciences (NASDAQ:BDSI).
In a statement, Mr. Mohanty said Dr. Patton brings a breadth and depth of legal experience and expertise in the biopharmaceutical industry and will make important contributions as BioTime continues to simplify its corporate structure, advances its clinical development programs, reports additional human data, leverages its sizeable intellectual property portfolio, and prepares for commercialization.
Dr. Patton said BioTime is well positioned with exciting clinical programs in aesthetics and ophthalmology that address multi-billion dollar global market opportunities.